Lupin launches Ipratropium Bromide nasal spray in US

Pharma major Lupin Ltd on Friday said it has launched Ipratropium Bromide nasal spray, used in treatment of runny nose, in the US market.

The Ipratropium Bromide nasal solution (nasal spray) launched in the US is of strengths 0.03 per cent and 0.06 per cent, Lupin Ltd said in a regulatory filing.

Ipratropium Bromide nasal spray 0.03 per cent and 0.06 per cent are bioequivalent to Atrovent nasal spray in the same strengths of Boehringer Ingelheim Pharmaceuticals, Inc, it added.

Lupin said Ipratropium Bromide nasal spray 0.03 per cent is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older.

Ipratropium Bromide nasal spray 0.06 per cent is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older, it added.

Citing IQVIA MAT May 2025 data, the company said Ipratropium Bromide nasal solution (Atrovent) had estimated annual sales of USD 63 million in the US.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)